{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T10:46:40Z","timestamp":1756896400806},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1991,1,1]],"date-time":"1991-01-01T00:00:00Z","timestamp":662688000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1991]]},"DOI":"10.1007\/bf00686334","type":"journal-article","created":{"date-parts":[[2004,11,29]],"date-time":"2004-11-29T08:44:58Z","timestamp":1101717898000},"page":"37-47","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer\/cytotoxin ?-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069)"],"prefix":"10.1007","volume":"29","author":[{"given":"Michael","family":"Binger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Workman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/bjc.1984.91","volume":"49","author":"GE Adams","year":"1984","unstructured":"Adams GE, Ahmed I, Sheldon PW, Stratford IJ (1984) Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer 49: 571","journal-title":"Br J Cancer"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2307\/3575246","volume":"82","author":"JM Brown","year":"1980","unstructured":"Brown JM, Workman P (1980) Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 82: 171","journal-title":"Radiat Res"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0360-3016(81)90460-0","volume":"7","author":"JM Brown","year":"1981","unstructured":"Brown JM, Yu NY, Brown DM, Lee WW (1981) A 2-nitro-imidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys 7: 695","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR4","doi-asserted-by":"crossref","unstructured":"Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC (1991) Dualfunction 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Radiat Res (in press)","DOI":"10.2307\/3577675"},{"key":"CR5","doi-asserted-by":"crossref","unstructured":"Cole S, Stratford IJ, Nolan J, Bowler J, Edwards H, Wright EG, Lorimore SA, Adams GE (1991) Oral dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral administration in mice. Int J Radiat Oncol Biol Phys (in press)","DOI":"10.1016\/0360-3016(91)90787-5"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/jnci\/80.5.310","volume":"80","author":"CN Coleman","year":"1988","unstructured":"Coleman CN (1988) Hypoxia in tumors: a paradigm for the approach to biochemical and physiologic heterogeneity. J Natl Cancer Inst 80: 310","journal-title":"J Natl Cancer Inst"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0167-8140(85)80015-3","volume":"3","author":"S Dische","year":"1985","unstructured":"Dische S (1985) Chemical sensitizers for hypoxic cells: a decade of experience in clinical radiotherapy. Radiother Oncol 3: 97","journal-title":"Radiother Oncol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/bjc.1986.128","volume":"53","author":"RP Hill","year":"1986","unstructured":"Hill RP, Gulyas S, Whitmore GF (1986) Studies of the in vivo and in vitro cytotoxicity of the drug RSU 1069. Br J Cancer 53: 743","journal-title":"Br J Cancer"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1259\/0007-1285-59-708-1238","volume":"59","author":"A Horwich","year":"1986","unstructured":"Horwich A, Holliday SB, Deacon JM, Peckham MJ (1986) A toxicity and pharmacokinetics study in man of the hypoxic-cell radiosensitizer RSU 1069. Br J Radiol 59: 1238","journal-title":"Br J Radiol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1021\/jm00171a040","volume":"33","author":"TC Jenkins","year":"1990","unstructured":"Jenkins TC, Naylor MA, O'Neill P, Threadgill MD, Cole S, Stratford IJ, Adams GE, Fielden M, Suto MJ, Stier MA (1990) Synthesis and evaluation of 1-3[(2-haloethylamino)propyl]-2-nitroimidazoles as prodrugs of RSU 1069 and its analogs which are radiosensitizers and bioreductively activated cytotoxins. J Med Chem 33: 2603","journal-title":"J Med Chem"},{"key":"CR11","first-page":"539","volume":"39","author":"RF Kallman","year":"1967","unstructured":"Kallman RF, Silini G, Putten LM van (1967) Factors influencing the quantitative estimation of the in vivo survival of cells from solid tumors. J Natl Cancer Inst 39: 539","journal-title":"J Natl Cancer Inst"},{"key":"CR12","first-page":"181","volume":"2","author":"KA Kennedy","year":"1987","unstructured":"Kennedy KA (1987) Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Design 2: 181","journal-title":"Anticancer Drug Design"},{"key":"CR13","series-title":"Proceedings of the 3rd International Meeting on Progress in Radio-Oncology","first-page":"137","volume-title":"Progress in radio-oncology III","author":"J Overgaard","year":"1987","unstructured":"Overgaard J, Hansen SH, Anderson AP, Hjelm-Handsen M, Jorgensen K, Sandberg K, Rygard J, Jensen RH, Peterson M (1987) Misonidazole as an adjuct to radiotherapy in the treatment of invasive carcinoma of the larynx and pharynx. In: Karcher KH, Kogelnik HD, Szepesi T (eds) Progress in radio-oncology III. Proceedings of the 3rd International Meeting on Progress in Radio-Oncology. ICRO, Vienna, pp 137?147"},{"key":"CR14","first-page":"509","volume":"116","author":"J Overgaard","year":"1990","unstructured":"Overgaard J, Sand Hansen H, Overgaard M, J\u00f8rgensen K, Rasmusson B, Berthelsen A (1990) Nimorazole as a hypoxic radiosensitizer in the treatment of larynx and pharynx carcinoma. First report from the Danish Head And Neck Cancer study (DAHANCA) protocol 5?85. J Cancer Res Clin Oncol 116: 509","journal-title":"J Cancer Res Clin Oncol"},{"key":"CR15","first-page":"1048","volume":"15","author":"HM Rauen","year":"1965","unstructured":"Rauen HM, Norpoth K, Kramer KP (1965) Das Schicksal von freiem Bis(?-chlorethyl)amin im Blutserum. Arzneimittelforschung 15: 1048","journal-title":"Arzneimittelforschung"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1259\/0007-1285-59-698-107","volume":"59","author":"JT Roberts","year":"1986","unstructured":"Roberts JT, Bleehen NM, Walton MI, Workman P (1986) A clinical phase I toxicity study of Ro 03-8799; plasma, urine tumour and normal brain pharmacokinetics. Br J Radiol 59: 107","journal-title":"Br J Radiol"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/0360-3016(84)90544-3","volume":"10","author":"MI Saunders","year":"1984","unstructured":"Saunders MI, Anderson PJ, Bennett MH, Dische S, Minchington A, Stratford MRL, Tothill M (1984) The clinical testing of Ro 03-8799: pharmacokinetics, toxicology, tissue and tumour concentrations. Int J Radiat Oncol Biol Phys 10: 1759","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/0006-2952(86)90146-2","volume":"35","author":"ARJ Silver","year":"1986","unstructured":"Silver ARJ, O'Niell P (1986) Interaction of the aziridine moiety of RSU 1069 with nucleotides and inorganic phosphate?implications for alkylation of DNA. Biochem Pharmacol 35: 1107","journal-title":"Biochem Pharmacol"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0006-2952(86)90566-6","volume":"35","author":"IJ Stratford","year":"1986","unstructured":"Stratford IJ, O'Neill P, Sheldon PW, Silver ARJ, Walling JM, Adams GE (1986) RSU 1069, a nitroimidazole containing an aziridine group. Bioreduction greatly increases cytotoxicity under hypoxic conditions. Biochem Pharmacol 35: 105?109","journal-title":"Biochem Pharmacol"},{"key":"CR20","unstructured":"Suto M (1988) United States Patent 07\/274, 209. United States Patent Office, Washington, D. C."},{"key":"CR21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/BF00254231","volume":"22","author":"MI Walton","year":"1988","unstructured":"Walton MI, Workman P (1988) Pharmacokinetics and metabolism of the mixed-function hypoxic cell sensitizer prototype RSU 1069 in mice. Cancer Chemother Pharmacol 22: 275","journal-title":"Cancer Chemother Pharmacol"},{"key":"CR22","first-page":"163","volume-title":"The control of tumour growth and its biological bases","author":"P Workman","year":"1983","unstructured":"Workman P (1983) Development of nitroimidazoles. In: Davis W, Maltoni C, Tanneberger SE (eds) The control of tumour growth and its biological bases. Springer, Berlin Heidelberg New York, pp 163?172"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/0360-3016(86)90267-1","volume":"12","author":"EM Zeman","year":"1986","unstructured":"Zeman EM, Brown JM, Lemmon MJ, Hirst VK, Lee WW (1986) SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. In J Radiat Oncol Biol Phys 12: 1239","journal-title":"In J Radiat Oncol Biol Phys"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00686334\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00686334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T11:13:55Z","timestamp":1585998835000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00686334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1991]]}},"alternative-id":["BF00686334"],"URL":"https:\/\/doi.org\/10.1007\/bf00686334","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1991]]}}}